
    
      This study has a randomized, open-label, three-treatment, one-sequence, placebo-controlled,
      multiple drug administration design. The purpose of this study is as follows; To evaluate
      pharmacokinetics, metabolomics and biomarker in subjects who are overweight and have liver
      problems after ursodeoxycholic acid administration
    
  